Time To Efficacy and Onset Of Action Of… | Clinical Trial

Key information

Conditions

Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

suspected grampositive infection
fever > 38 C

Exclusion criteria

Infections to be treated successfully by surgical procedures

Treatment and study plan

Linezolid

Drug

Primary outcomes

Time to defervescence

Secondary outcomes

Reduction of CRP levels Reduction of leucocyte count

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Important dates

Study start: 2003
Study completion: 2005
First posted: Sep 7, 2005
Registry last updated: May 10, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed